Navigation Links
Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Date:7/7/2011

t of SEGA response rate, with 35% of patients (27 of 78) receiving everolimus experiencing a 50% or greater reduction in SEGA volume (sum of volumes of all target SEGAs) relative to baseline versus 0% of patients (0 of 39) on placebo (p<0.0001)(1).

"This study, which included SEGA patients from infancy to adulthood, provides compelling evidence of the impact of everolimus in reducing SEGA size with a tolerability profile consistent with the previous everolimus trial in this treatment setting," said Dr. Sergiusz Jozwiak, a lead EXIST-1 investigator and Professor, Department of Child Neurology, The Children's Memorial Health Institute, Warsaw, Poland. "This is very good news for patients and caregivers in many countries who currently may face brain surgery as the only treatment option for growing SEGAs."

Everolimus targets mTOR, a protein that acts as an important regulator of tumor cell division, blood vessel growth and cell metabolism(9). Tuberous sclerosis complex is caused by defects in the TSC1 and/or TSC2 genes. When these genes are defective, mTOR activity is increased, which can cause uncontrolled tumor cell growth and proliferation, blood vessel growth and altered cellular metabolism, leading to the formation of non-cancerous tumors throughout the body, including the brain. By inhibiting mTOR activity in this signaling pathway, everolimus may reduce cell proliferation, blood vessel growth and glucose uptake related to SEGA associated with TSC(2,6).

"The positive results seen in the Phase III trial point to the important role of everolimus and mTOR inhibition in SEGA associated with TSC," said Herve Hoppenot, President, Novartis Oncology. "This outcome is welcome news as we continue our research efforts to fully understand the potential of this important treatment option across the wide range of disorders associated with TSC."

The Phase III study supports the findings of the Phase II study used for registration in s
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
2. GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
3. Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal
4. Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain
5. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
6. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
7. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
8. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
9. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
10. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
11. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Ill. , Sept. 22, 2014  AbbVie ... from several clinical studies evaluating potential new medicines ... at the upcoming 2014 European Society of Medical ... Madrid, Spain . Data being presented ... the safety and efficacy of veliparib (ABT-888), a ...
(Date:9/22/2014)... , Sept. 22, 2014  Seres Health, a ... to the human microbiome, today announced that it has ... 2014,s Fierce 15 biotechnology companies, designating it as one ... industry.  "Amid a great deal of ... its focus and commitment to practical therapeutic development," says ...
(Date:9/22/2014)... 22, 2014 Research and Markets  has ... Diclofenac Industry Report 2014" report to their offering. ... Report 2014 is a professional and in-depth study on ... a focus on the Chinese situation. The ... definitions, classifications, applications and industry chain structure. The diclofenac ...
Breaking Medicine Technology:AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Seres Health Named a "Fierce 15" Biotech Company for 2014 2Global and Chinese Diclofenac Industry Report 2014 2
... 2011 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) ... will present a company update at the Wedbush Life Sciences ... 10:00 a.m. ET. Interested parties may access a ... section of the BioMarin website, www.BMRN.com .  A replay ...
... 2011 Healthy Advice ® Networks, the ... engagement programs at point-of-care, announces that their partner, ... promote the Food and Drug Administration,s campaign, educating ... pain relievers. Partnering with MediaForce PR, Healthy ...
Cached Medicine Technology:BioMarin to Present at the Wedbush Life Sciences Conference 2Healthy Advice® Networks Partners With MediaForce PR to Deliver Public Service Announcements to Educate Consumers About Appropriate Use of Prescription Medications 2Healthy Advice® Networks Partners With MediaForce PR to Deliver Public Service Announcements to Educate Consumers About Appropriate Use of Prescription Medications 3
(Date:9/22/2014)... today became a founding partner in the Global STEM ... promoting young talent in science, technology, engineering and math ... York Academy of Sciences (NYAS), Malaysian Prime Minister Najib ... Sept. 22. , With the goal of developing over ... by 2020, the initiative will create a host of ...
(Date:9/22/2014)... -- Recent two-generation approaches to reducing poverty that ... attention from researchers, advocates, and foundations. By combining ... to move to jobs that offer a path ... education for children, these programs aim to improve ... to a new report from the National Center ...
(Date:9/22/2014)... New York (PRWEB) September 22, 2014 ... with the use of power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ... notes a new report detailing the continued use ... from federal regulators that specifically discouraged these procedures. ... believe that the potential cancer risks associated with ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Pain does not ... Pain” is a user- and reader-friendly book designed to guide ... to pain-free living. This inspirational book is written to help ... to know a way to regain a pain-free life — ... of chronic pain. , Chronic pain has become an epidemic, ...
(Date:9/22/2014)... 2014) Montefiore Medical Center, Albert Einstein College of Medicine ... received a $300,000 grant from The Agency for Healthcare ... health Information Technology (IT) on patient safety. , This ... important clinical patient safety issue impacted by health IT. ... first time IT leaders have data on the risk ...
Breaking Medicine News(10 mins):Health News:Growing scientists: World's future jobs are rooted in STEM 2Health News:Growing scientists: World's future jobs are rooted in STEM 3Health News:A two-generation lens: Current state policies fail to support families with young children 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Naturopathic Doctor Inspires and Guides Those Who Suffer with Chronic Pain, Pointing the Way Back to Pain-free Living 2Health News:AHRQ grant awarded to study the impact of health IT on patient safety at Montefiore and Einstein and Brigham and Women's Hospital 2
... 23 NxStage Medical, Inc.,(Nasdaq: NXTM ), a ... million private placement of its common stock and,warrants. The ... stock at a price of $4.50 per share and ... an exercise price of $5.50 per share,which price may ...
... 23 Dr. Nancy Minshew, a,leading researcher on the ... work in a presentation co-sponsored by the Pennsylvania,Cyber Charter ... diagnosed with autism. Students with,autism and other special needs ... its mission, is committed to focusing on the needs ...
... University,Medical Center (MUMC) now offers a type of ... the belly button. It,s called single,incision laparoscopic surgery, ... in the SILS technique. One of them is ... remove the gallbladder through a,1cm. incision in the ...
... MDNG, a publication that,reaches nearly a quarter ... discussion that will provide physicians an opportunity,to speak ... unique,practice model has made him a household name. ... 2008, at 8:00 p.m. EDT at, http://www.mdnglive.com/chat/JayParkinson ., ...
... 500,000 to make a world of difference for Singer Songwriter Katie ... Reider Beginning ... years, Cincinnati-based,singer songwriter Katie Reider, age 29, has inspired the hearts ... within. Fans across the country are banding together to help Katie,during ...
... ... health in the Western world, the, Omega-3 story may someday be viewed ... - William S. Harris, PhD, American ... Nutrition (2003), COLUMBUS, Ohio, May 23 If anyone needed another reason,to ...
Cached Medicine News:Health News:NxStage Announces $43 Million Private Placement of Equity Securities 2Health News:NxStage Announces $43 Million Private Placement of Equity Securities 3Health News:NxStage Announces $43 Million Private Placement of Equity Securities 4Health News:Dr. Nancy Minshew, Autism Researcher, to Speak at Regional Learning Alliance in Cranberry Township 2Health News:SILS Surgical Technique Now Available at MUMC 2Health News:MDNG Offers Free Online Discussion With Maverick Physician Jay Parkinson, M.D. 2Health News:Katie Reider - Listen to Her Songs, Hear Her Story, Log Onto www.500kin365.org 2Health News:Katie Reider - Listen to Her Songs, Hear Her Story, Log Onto www.500kin365.org 3Health News:Announcing Another Great Reason to Eat Chocolate 2
... Aplicare's Prep-Swab Ampule is a ... plastic tube that is sealed ... an absorbent applicator at the ... is squeezed to break the ...
... a valuable tool in standardizing protocols for ... for a procedure are supplied in a ... care are easier to be established and ... use, allowing the clinician to progress efficiently ...
... Patient preoperative skin preparation ... surgical site infections. Scrub Care ... trays offer high efficacy and ... , Prevail-Fx offers the highest ...
... Anti-HCV Low Titer Performance Panel consists of ... to strong positive for antibodies to the ... for use by manufacturers and diagnostic laboratories ... from all major test systems are included ...
Medicine Products: